{
    "abstract": "Background: Individuals with functional or anatomic asplenia are at high risk for meningococcal disease. We evaluated the immunogenicity and safety of 1 and 2 doses of the quadrivalent meningococcal serogroups A, C, W, Y tetanus toxoid-conjugate vaccine (MenACWY-TT) in this high-risk population. Methods: This phase III, open-label, controlled, non-randomized study (NCT01641042) enrolled 1\u201317-year-olds with impaired splenic activity (high-risk group) and age-matched healthy controls (control group). We measured immune responses to MenACWY-TT by serum bactericidal activity assays using rabbit (rSBA) and human (hSBA) complement and in terms of antibodies against polysaccharides of the 4 vaccine serogroups. We evaluated vaccine response rates (VRRs) as 4-fold increases from pre-vaccination levels or titers \u22651:32 (rSBA)/\u22651:8 (hSBA). We recorded solicited and unsolicited adverse events (AEs) during 4 and 31 days post-vaccination, and serious AEs (SAEs) and new onset of chronic illnesses (NOCIs) throughout the study. Results: The according-to-protocol cohort for immunogenicity included 40 participants per group. In both groups, the first MenACWY-TT dose induced rSBA VRRs of 92.5\u2013100% and hSBA VRRs of 55.6\u201377.1% across vaccine serogroups. Following the second MenACWY-TT dose, all participants had high responses, with rSBA and hSBA VRRs of 73.0\u2013100% across vaccine serogroups. rSBA and hSBA geometric mean titers for each serogroup increased in both groups (with different magnitudes, but \u226513.1-fold) compared with baseline levels. Polysaccharide antibody concentrations \u22652.0 \u03bcg/ml were detected in \u226584.4% of participants and were similar between groups. Incidences of solicited and unsolicited AEs were comparable between groups. We recorded SAEs in 4/43 participants in the high-risk group and 1/43 participants in the control group (none vaccine-related). No NOCIs were reported. Conclusion: In this descriptive study, MenACWY-TT induced similar functional and humoral immune responses and had a clinically acceptable safety profile in children and adolescents with impaired splenic activity and in healthy controls.",
    "author_highlights": [
        {
            "endOffset": 16609,
            "sentence": "Anatomic/functional asplenia increases the risk of meningococcal disease.",
            "startOffset": 16536
        },
        {
            "endOffset": 16694,
            "sentence": "We evaluated immunogenicity of 1 and 2 MenACWY-TT doses in high-risk 1\u201317-year-olds.",
            "startOffset": 16610
        },
        {
            "endOffset": 16779,
            "sentence": "We observed similar rSBA/hSBA vaccine responses in the high-risk and control groups.",
            "startOffset": 16695
        },
        {
            "endOffset": 16854,
            "sentence": "Humoral immune response did not seem to be impacted in high-risk patients.",
            "startOffset": 16780
        },
        {
            "endOffset": 16924,
            "sentence": "2 doses of MenACWY-TT had a comparable safety profile in both groups.",
            "startOffset": 16855
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Crum-Cianflone"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Sullivan"
                }
            ],
            "doi": "10.1007/s40121-016-0107-0",
            "firstpage": "89",
            "issn": "21938229",
            "lastpage": "112",
            "pub_year": 2016,
            "title": "Meningococcal Vaccinations",
            "volume": "5"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Dwilow"
                },
                {
                    "first": "Sergio",
                    "initial": "S.",
                    "last": "Fanella"
                }
            ],
            "doi": "10.1007/s11910-015-0524-6",
            "issn": "15284042",
            "pmid": "25637287",
            "pub_year": 2015,
            "title": "Invasive Meningococcal Disease in the 21st Century\u2014An Update for the Clinician",
            "volume": "15"
        },
        "b0015": null,
        "b0020": {
            "authors": [
                {
                    "first": "H. David",
                    "initial": "H.D.",
                    "last": "Pettigrew"
                },
                {
                    "first": "Suzanne S.",
                    "initial": "S.S.",
                    "last": "Teuber"
                },
                {
                    "first": "M. Eric",
                    "initial": "M.E.",
                    "last": "Gershwin"
                }
            ],
            "doi": "10.1111/j.1749-6632.2009.04633.x",
            "firstpage": "108",
            "issn": "00778923",
            "lastpage": "123",
            "pmid": "19758139",
            "pub_year": 2009,
            "title": "Clinical significance of complement deficiencies",
            "volume": "1173"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Ram"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Lewis"
                },
                {
                    "first": "Peter A.",
                    "initial": "P.A.",
                    "last": "Rice"
                }
            ],
            "doi": "10.1128/CMR.00048-09",
            "firstpage": "740",
            "issn": "08938512",
            "lastpage": "780",
            "pmid": "20930072",
            "pub_year": 2010,
            "title": "Infections of people with complement deficiencies and patients who have undergone splenectomy",
            "volume": "23"
        },
        "b0030": {
            "authors": [
                {
                    "first": "E. G.",
                    "initial": "E.G.",
                    "last": "Mourtzoukou"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Pappas"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Peppas"
                },
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Falagas"
                }
            ],
            "doi": "10.1002/bjs.6106",
            "firstpage": "273",
            "issn": "00071323",
            "lastpage": "280",
            "pmid": "18278784",
            "pub_year": 2008,
            "title": "Vaccination of asplenic or hyposplenic adults",
            "volume": "95"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Temitope",
                    "initial": "T.",
                    "last": "Folaranmi"
                },
                {
                    "first": "Lorry",
                    "initial": "L.",
                    "last": "Rubin"
                },
                {
                    "first": "Stacey W.",
                    "initial": "S.W.",
                    "last": "Martin"
                },
                {
                    "first": "Manisha",
                    "initial": "M.",
                    "last": "Patel"
                },
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "Macneil"
                }
            ],
            "firstpage": "608",
            "issn": "01492195",
            "lastpage": "612",
            "pmid": "26068564",
            "pub_year": 2015,
            "title": "Use of serogroup b meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup b meningococcal disease: Recommendations of the advisory committee on immunization practices, 2015",
            "volume": "64"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Amanda C.",
                    "initial": "A.C.",
                    "last": "Cohn"
                },
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                },
                {
                    "first": "Ismael R.",
                    "initial": "I.R.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Elizabeth Z.",
                    "initial": "E.Z.",
                    "last": "Briere"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Cody Meissner"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                }
            ],
            "issn": "10575987",
            "pmid": "23515099",
            "pub_year": 2013,
            "title": "Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)",
            "volume": "62"
        },
        "b0045": {
            "authors": [
                {
                    "first": "M. A.",
                    "initial": "M.A.",
                    "last": "Breukels"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Zandvoort"
                },
                {
                    "first": "G. P.J.M.",
                    "initial": "G.P.J.M.",
                    "last": "Van den Dobbelsteen"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Van den Muijsenberg"
                },
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Lodewijk"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Beurret"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Klok"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Timens"
                },
                {
                    "first": "G. T.",
                    "initial": "G.T.",
                    "last": "Rijkers"
                }
            ],
            "doi": "10.1128/IAI.69.12.7583-7587.2001",
            "firstpage": "7583",
            "issn": "00199567",
            "lastpage": "7587",
            "pmid": "11705936",
            "pub_year": 2001,
            "title": "Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides",
            "volume": "69"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Deborah C.",
                    "initial": "D.C.",
                    "last": "Molrine"
                },
                {
                    "first": "George R.",
                    "initial": "G.R.",
                    "last": "Siber"
                },
                {
                    "first": "Yecheskel",
                    "initial": "Y.",
                    "last": "Samra"
                },
                {
                    "first": "Drora",
                    "initial": "D.",
                    "last": "Samra Shevy"
                },
                {
                    "first": "Kristin",
                    "initial": "K.",
                    "last": "MacDonald"
                },
                {
                    "first": "Rocco",
                    "initial": "R.",
                    "last": "Cieri"
                },
                {
                    "first": "Donna M.",
                    "initial": "D.M.",
                    "last": "Ambrosino"
                }
            ],
            "doi": "10.1086/314582",
            "firstpage": "513",
            "issn": "00221899",
            "lastpage": "517",
            "pmid": "9878041",
            "pub_year": 1999,
            "title": "Normal IgG and impaired IgM responses to polysaccharide vaccines in asplenic patients",
            "volume": "179"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Balmer"
                },
                {
                    "first": "Michelle",
                    "initial": "M.",
                    "last": "Falconer"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "McDonald"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Fuller"
                },
                {
                    "first": "Christine",
                    "initial": "C.",
                    "last": "Riley"
                },
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Kaczmarski"
                },
                {
                    "first": "Raymond",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1128/IAI.72.1.332-337.2004",
            "firstpage": "332",
            "issn": "00199567",
            "lastpage": "337",
            "pmid": "14688112",
            "pub_year": 2004,
            "title": "Immune Response to Meningococcal Serogroup C Conjugate Vaccine in Asplenic Individuals",
            "volume": "72"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Vana",
                    "initial": "V.",
                    "last": "Spoulou"
                },
                {
                    "first": "Georgina",
                    "initial": "G.",
                    "last": "Tzanakaki"
                },
                {
                    "first": "Sophia",
                    "initial": "S.",
                    "last": "Lekka"
                },
                {
                    "first": "Giorgos",
                    "initial": "G.",
                    "last": "Chouliaras"
                },
                {
                    "first": "Vassilis",
                    "initial": "V.",
                    "last": "Ladis"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Theodoridou"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.03.080",
            "firstpage": "4435",
            "issn": "0264410X",
            "lastpage": "4438",
            "pmid": "21497638",
            "pub_year": 2011,
            "title": "Natural and vaccine-induced immunity to Neisseria meningitidis serogroup C in asplenic patients with \u03b2-thalassemia",
            "volume": "29"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Kim",
                    "initial": "K.",
                    "last": "Kristensen"
                }
            ],
            "doi": "10.3109/00365549209054649",
            "firstpage": "629",
            "issn": "00365548",
            "lastpage": "632",
            "pmid": "1465581",
            "pub_year": 1992,
            "title": "Antibody response to a haemophilus influenzae type b polysaccharide tetanus toxoid conjugate vaccine in splenectomized children and adolescents",
            "volume": "24"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Thomas V.",
                    "initial": "T.V.",
                    "last": "Adamkiewicz"
                },
                {
                    "first": "Benjamin J.",
                    "initial": "B.J.",
                    "last": "Silk"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Howgate"
                },
                {
                    "first": "Wendy",
                    "initial": "W.",
                    "last": "Baughman"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Strayhorn"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Sullivan"
                },
                {
                    "first": "Monica M.",
                    "initial": "M.M.",
                    "last": "Farley"
                }
            ],
            "doi": "10.1542/peds.2007-0018",
            "firstpage": "562",
            "issn": "00314005",
            "lastpage": "569",
            "pmid": "18310206",
            "pub_year": 2008,
            "title": "Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life",
            "volume": "121"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Natasha B.",
                    "initial": "N.B.",
                    "last": "Halasa"
                },
                {
                    "first": "Sadhna M.",
                    "initial": "S.M.",
                    "last": "Shankar"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Talbot"
                },
                {
                    "first": "Patrick G.",
                    "initial": "P.G.",
                    "last": "Arbogast"
                },
                {
                    "first": "Ed F.",
                    "initial": "E.F.",
                    "last": "Mitchel"
                },
                {
                    "first": "Winfred C.",
                    "initial": "W.C.",
                    "last": "Wang"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Schaffner"
                },
                {
                    "first": "Allen S.",
                    "initial": "A.S.",
                    "last": "Craig"
                },
                {
                    "first": "Marie R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                }
            ],
            "doi": "10.1086/516781",
            "firstpage": "1428",
            "issn": "10584838",
            "lastpage": "1433",
            "pmid": "17479937",
            "pub_year": 2007,
            "title": "Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine",
            "volume": "44"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Kruetzmann"
                },
                {
                    "first": "M. Manuela",
                    "initial": "M.M.",
                    "last": "Rosado"
                },
                {
                    "first": "Holger",
                    "initial": "H.",
                    "last": "Weber"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Germing"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Tournilhac"
                },
                {
                    "first": "Hans Hartmut",
                    "initial": "H.H.",
                    "last": "Peter"
                },
                {
                    "first": "Reinhard",
                    "initial": "R.",
                    "last": "Berner"
                },
                {
                    "first": "Anke",
                    "initial": "A.",
                    "last": "Peters"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Boehm"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Plebani"
                },
                {
                    "first": "Isabella",
                    "initial": "I.",
                    "last": "Quinti"
                },
                {
                    "first": "Rita",
                    "initial": "R.",
                    "last": "Carsetti"
                }
            ],
            "doi": "10.1084/jem.20022020",
            "firstpage": "939",
            "issn": "00221007",
            "lastpage": "945",
            "pmid": "12682112",
            "pub_year": 2003,
            "title": "Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen",
            "volume": "197"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                },
                {
                    "first": "Lorry",
                    "initial": "L.",
                    "last": "Rubin"
                },
                {
                    "first": "Lucy",
                    "initial": "L.",
                    "last": "McNamara"
                },
                {
                    "first": "Elizabeth C.",
                    "initial": "E.C.",
                    "last": "Briere"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                },
                {
                    "first": "Amanda C.",
                    "initial": "A.C.",
                    "last": "Cohn"
                }
            ],
            "firstpage": "527",
            "issn": "01492195",
            "lastpage": "530",
            "pmid": "24941332",
            "pub_year": 2014,
            "title": "Use of menACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: Recommendations of the advisory committee on immunization practices, 2013"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Aia",
                    "initial": "A.",
                    "last": "Assaf-Casals"
                },
                {
                    "first": "Ghassan",
                    "initial": "G.",
                    "last": "Dbaibo"
                }
            ],
            "doi": "10.1080/21645515.2016.1143157",
            "firstpage": "1825",
            "issn": "21645515",
            "lastpage": "1837",
            "pmid": "26900984",
            "pub_year": 2016,
            "title": "Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix\u2122): A review of its immunogenicity, safety, co-administration, and antibody persistence",
            "volume": "12"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Vassiliki",
                    "initial": "V.",
                    "last": "Papaevangelou"
                },
                {
                    "first": "Nikos",
                    "initial": "N.",
                    "last": "Spyridis"
                }
            ],
            "doi": "10.1586/erv.12.32",
            "firstpage": "523",
            "issn": "14760584",
            "lastpage": "537",
            "pmid": "22827239",
            "pub_year": 2012,
            "title": "MenACWY-TT vaccine for active immunization against invasive meningococcal disease",
            "volume": "11"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Jamie D.",
                    "initial": "J.D.",
                    "last": "Croxtall"
                },
                {
                    "first": "Sohita",
                    "initial": "S.",
                    "last": "Dhillon"
                }
            ],
            "doi": "10.2165/11209580-000000000-00000",
            "firstpage": "2407",
            "issn": "00126667",
            "lastpage": "2430",
            "pmid": "23231026",
            "pub_year": 2012,
            "title": "Meningococcal quadrivalent (Serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix\u2122)",
            "volume": "72"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Di Sabatino"
                },
                {
                    "first": "Rita",
                    "initial": "R.",
                    "last": "Carsetti"
                },
                {
                    "first": "Gino Roberto",
                    "initial": "G.R.",
                    "last": "Corazza"
                }
            ],
            "doi": "10.1016/S0140-6736(10)61493-6",
            "firstpage": "86",
            "issn": "01406736",
            "lastpage": "97",
            "pmid": "21474172",
            "pub_year": 2011,
            "title": "Post-splenectomy and hyposplenic states",
            "volume": "378"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Doug",
                    "initial": "D.",
                    "last": "Campos-Outcalt"
                }
            ],
            "firstpage": "699",
            "issn": "00943509",
            "lastpage": "701",
            "pmid": "21135925",
            "pub_year": 2010,
            "title": "ACIP update: 2 new recommendations for meningococcal vaccine",
            "volume": "59"
        },
        "b0115": {
            "authors": [],
            "doi": "10.1001/jama.2013.281053",
            "firstpage": "2191",
            "issn": "00987484",
            "lastpage": "2194",
            "pmid": "24141714",
            "pub_year": 2013,
            "title": "World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects",
            "volume": "310"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1128/CDLI.10.5.780-786.2003",
            "firstpage": "780",
            "issn": "1071412X",
            "lastpage": "786",
            "pmid": "12965904",
            "pub_year": 2003,
            "title": "Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England",
            "volume": "10"
        },
        "b0125": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1327",
            "firstpage": "1327",
            "issn": "00221007",
            "lastpage": "1348",
            "pmid": "4977281",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. II. Development of natural immunity.",
            "volume": "129"
        },
        "b0130": {
            "authors": [
                {
                    "first": "E. D.G.",
                    "initial": "E.D.G.",
                    "last": "McIntosh"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Br\u00f6ker"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Wassil"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.07.019",
            "firstpage": "4414",
            "issn": "0264410X",
            "lastpage": "4421",
            "pmid": "26187262",
            "pub_year": 2015,
            "title": "Serum bactericidal antibody assays - The role of complement in infection and immunity",
            "volume": "33"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Balmer"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2005.01.051",
            "firstpage": "2222",
            "issn": "0264410X",
            "lastpage": "2227",
            "pmid": "15755600",
            "pub_year": 2005,
            "title": "Meningococcal surrogates of protection - Serum bactericidal antibody activity",
            "volume": "23"
        },
        "b0140": {
            "authors": [
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Shadomy"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Plikaytis"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Clark"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Carlone"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Messonnier"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Uhde"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Winger"
                }
            ],
            "firstpage": "1016",
            "issn": "01492195",
            "lastpage": "1017",
            "pmid": "16988640",
            "pub_year": 2006,
            "title": "Inadvertent misadministration of meningococcal conjugate vaccine - United States, June-August 2005",
            "volume": "55"
        },
        "b0145": {
            "authors": [
                {
                    "first": "L. L.",
                    "initial": "L.L.",
                    "last": "Gheesling"
                },
                {
                    "first": "G. M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                },
                {
                    "first": "L. B.",
                    "initial": "L.B.",
                    "last": "Pais"
                },
                {
                    "first": "P. F.",
                    "initial": "P.F.",
                    "last": "Holder"
                },
                {
                    "first": "S. E.",
                    "initial": "S.E.",
                    "last": "Maslanka"
                },
                {
                    "first": "B. D.",
                    "initial": "B.D.",
                    "last": "Plikaytis"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Achtman"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Densen"
                },
                {
                    "first": "C. E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Kayhty"
                },
                {
                    "first": "J. P.",
                    "initial": "J.P.",
                    "last": "Mays"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Nencioni"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Peeters"
                },
                {
                    "first": "D. C.",
                    "initial": "D.C.",
                    "last": "Phipps"
                },
                {
                    "first": "J. T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Rosenqvist"
                },
                {
                    "first": "G. R.",
                    "initial": "G.R.",
                    "last": "Siber"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Thiesen"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Tai"
                }
            ],
            "firstpage": "1475",
            "issn": "00951137",
            "lastpage": "1482",
            "pmid": "8077392",
            "pub_year": 1994,
            "title": "Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay",
            "volume": "32"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Heikki",
                    "initial": "H.",
                    "last": "Peltola"
                }
            ],
            "doi": "10.2165/00003495-199855030-00003",
            "firstpage": "347",
            "issn": "00126667",
            "lastpage": "366",
            "pmid": "9530542",
            "pub_year": 1998,
            "title": "Meningococcal vaccines",
            "volume": "55"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Moira E.",
                    "initial": "M.E.",
                    "last": "Melville-Smith"
                },
                {
                    "first": "Valerie A.",
                    "initial": "V.A.",
                    "last": "Seagroatt"
                },
                {
                    "first": "Johanna T.",
                    "initial": "J.T.",
                    "last": "Watkins"
                }
            ],
            "doi": "10.1016/S0092-1157(83)80038-9",
            "firstpage": "137",
            "issn": "00921157",
            "lastpage": "144",
            "pmid": "6345548",
            "pub_year": 1983,
            "title": "A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera",
            "volume": "11"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Ensor"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0b013e3182054ab9",
            "firstpage": "e41",
            "issn": "08913668",
            "lastpage": "e48",
            "pub_year": 2011,
            "title": "Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age",
            "volume": "30"
        },
        "b0165": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Kieninger-Baum"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Habermehl"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Muttonen"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Maurer"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Vink"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Boutriau"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.10.064",
            "firstpage": "744",
            "issn": "0264410X",
            "lastpage": "753",
            "pmid": "19887137",
            "pub_year": 2010,
            "title": "A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children",
            "volume": "28"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Ziad A.",
                    "initial": "Z.A.",
                    "last": "Memish"
                },
                {
                    "first": "Ghassan",
                    "initial": "G.",
                    "last": "Dbaibo"
                },
                {
                    "first": "May",
                    "initial": "M.",
                    "last": "Montellano"
                },
                {
                    "first": "Valsan P.",
                    "initial": "V.P.",
                    "last": "Verghese"
                },
                {
                    "first": "Hemant",
                    "initial": "H.",
                    "last": "Jain"
                },
                {
                    "first": "A. P.",
                    "initial": "A.P.",
                    "last": "Dubey"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Salvacion",
                    "initial": "S.",
                    "last": "Gatchalian"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0b013e31820e6e02",
            "firstpage": "e56",
            "issn": "08913668",
            "lastpage": "e62",
            "pmid": "21278617",
            "pub_year": 2011,
            "title": "Immunogenicity of a single dose of tetravalent meningococcal serogroups a, c, w-135, and y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-acwy polysaccharide vaccine with an acceptable safety profile",
            "volume": "30"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Romain"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Kindler"
                },
                {
                    "first": "Uta",
                    "initial": "U.",
                    "last": "Walther"
                },
                {
                    "first": "Phu My",
                    "initial": "P.M.",
                    "last": "Tran"
                },
                {
                    "first": "Heidemarie",
                    "initial": "H.",
                    "last": "Pankow-Culot"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Fischbach"
                },
                {
                    "first": "Dorothee",
                    "initial": "D.",
                    "last": "Kieninger-Baum"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1007/s00431-012-1924-0",
            "firstpage": "601",
            "issn": "03406199",
            "lastpage": "612",
            "pmid": "23307281",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: Results of an open, randomised, controlled study",
            "volume": "172"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forst\u00e9n"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.4161/hv.22165",
            "firstpage": "1882",
            "issn": "21645515",
            "lastpage": "1891",
            "pmid": "23032168",
            "pub_year": 2012,
            "title": "A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine in children aged 2-10 y",
            "volume": "8"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Joseph B.",
                    "initial": "J.B.",
                    "last": "Domachowske"
                },
                {
                    "first": "Naresh",
                    "initial": "N.",
                    "last": "Aggarwal"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Simon"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Shelly A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Carmen I.",
                    "initial": "C.I.",
                    "last": "Baccarini"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1093/jpids/pit058",
            "firstpage": "33",
            "issn": "20487193",
            "lastpage": "42",
            "pub_year": 2014,
            "title": "Comparison of the safety and immunogenicity of a novel quadrivalent meningococcal ACWY-Tetanus toxoid conjugate vaccine and a marketed quadrivalent meningococcal ACWY-Diphtheria toxoid conjugate vaccine in healthy individuals 10-25 years of age",
            "volume": "3"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Pascal R.",
                    "initial": "P.R.",
                    "last": "Lestrate"
                },
                {
                    "first": "Aftab",
                    "initial": "A.",
                    "last": "Naz"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Blatter"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0b013e31828693c5",
            "firstpage": "760",
            "issn": "08913668",
            "lastpage": "767",
            "pmid": "23348814",
            "pub_year": 2013,
            "title": "One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine is immunogenic in 9-to 12-month-old children",
            "volume": "32"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Ana Cristina C.",
                    "initial": "A.C.C.",
                    "last": "Frota"
                },
                {
                    "first": "Lucimar G.",
                    "initial": "L.G.",
                    "last": "Milagres"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Bianca",
                    "initial": "B.",
                    "last": "Ferreira"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Menna Barreto"
                },
                {
                    "first": "Gisele S.",
                    "initial": "G.S.",
                    "last": "Pereira"
                },
                {
                    "first": "Aline C.",
                    "initial": "A.C.",
                    "last": "Cruz"
                },
                {
                    "first": "Wania",
                    "initial": "W.",
                    "last": "Pereira-Manfro"
                },
                {
                    "first": "Ricardo Hugo",
                    "initial": "R.H.",
                    "last": "De Oliveira"
                },
                {
                    "first": "Thalita F.",
                    "initial": "T.F.",
                    "last": "Abreu"
                },
                {
                    "first": "Cristina B.",
                    "initial": "C.B.",
                    "last": "Hofer"
                }
            ],
            "doi": "10.1097/INF.0000000000000630",
            "firstpage": "e113",
            "issn": "08913668",
            "lastpage": "e118",
            "pmid": "25876102",
            "pub_year": 2015,
            "title": "Immunogenicity and safety of Meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil",
            "volume": "34"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Hoare"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "El-Shazali"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Clark"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Fay"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Cant"
                }
            ],
            "doi": "10.1136/adc.86.3.215",
            "firstpage": "215",
            "issn": "00039888",
            "lastpage": "217",
            "pmid": "11861251",
            "pub_year": 2002,
            "title": "Investigation for complement deficiency following meningococcal disease",
            "volume": "86"
        }
    },
    "body_text": [
        {
            "endOffset": 24582,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All parents/legally acceptable representatives signed an informed consent form prior to enrolment; participants aged \u22657 years signed an informed assent.",
            "startOffset": 24430,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29454,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-dose 2, all participants from both groups were responders (Table 2, Supplementary Material, Table S1).",
            "startOffset": 29337,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 34470,
            "parents": [],
            "secId": "s0070",
            "sentence": "Most participants in both groups responded to 1 or 2 MenACWY-TT doses, with rSBA VRRs \u226592.5% and hSBA VRRs \u226573.0%, demonstrating the immunogenicity of MenACWY-TT in high-risk individuals.",
            "startOffset": 34283,
            "title": "Discussion"
        },
        {
            "endOffset": 41264,
            "parents": [],
            "secId": "s0090",
            "sentence": "All authors reviewed and commented critically drafts of the manuscript for important intellectual content and gave final approval to submit for publication.",
            "startOffset": 41108,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 38031,
            "parents": [],
            "refoffsets": {
                "b0195": {
                    "endOffset": 38030,
                    "startOffset": 38026
                }
            },
            "secId": "s0070",
            "sentence": "A similar trend was previously observed in a different, medically-vulnerable population, where higher rates of AEs were observed during 3 days post-immunization with meningococcal vaccines in HIV-infected compared with uninfected children [39].",
            "startOffset": 37787,
            "title": "Discussion"
        },
        {
            "endOffset": 39731,
            "parents": [],
            "secId": "s0070",
            "sentence": "Finally, this study was limited by the unknown relevance of SBA assays for this population since induced antibodies may not be as effective in asplenic children as in children with a healthy spleen.",
            "startOffset": 39533,
            "title": "Discussion"
        },
        {
            "endOffset": 24311,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "One 0.5 mL dose of MenACWY-TT contains 5 \u00b5g of each of the capsular PSs (MenA, MenC, MenW and MenY) conjugated to TT (\u223c44 \u00b5g).",
            "startOffset": 24185,
            "title": "Study design and participants"
        },
        {
            "endOffset": 40457,
            "parents": [],
            "secId": "s0075",
            "sentence": "Future studies should evaluate the effectiveness of MenACWY-TT in this high-risk population.",
            "startOffset": 40365,
            "title": "Conclusion"
        },
        {
            "endOffset": 20501,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 20500,
                    "startOffset": 20493
                },
                "b0020": {
                    "endOffset": 20500,
                    "startOffset": 20493
                },
                "b0035": {
                    "endOffset": 20500,
                    "startOffset": 20493
                }
            },
            "secId": "s0005",
            "sentence": "These conditions induce an up to 10,000-fold higher risk of invasive meningococcal disease and higher mortality rates (40\u201370%) compared with healthy populations [1,4,7].",
            "startOffset": 20332,
            "title": "Introduction"
        },
        {
            "endOffset": 35894,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 35893,
                    "startOffset": 35886
                },
                "b0175": {
                    "endOffset": 35893,
                    "startOffset": 35886
                },
                "b0180": {
                    "endOffset": 35893,
                    "startOffset": 35886
                }
            },
            "secId": "s0070",
            "sentence": "Similarly, \u226599.5% of MenACWY-TT recipients had rSBA titers \u22651:8 and VRRs were \u226588.6% for each vaccine serogroup in 3 studies in healthy 2\u201310-year-olds [34\u201336].",
            "startOffset": 35735,
            "title": "Discussion"
        },
        {
            "endOffset": 39926,
            "parents": [],
            "secId": "s0070",
            "sentence": "However, it addressed an important scientific gap since efficacy trials are infeasible in this high-risk population due to the large sample size needed and the relative rarity of the conditions.",
            "startOffset": 39732,
            "title": "Discussion"
        },
        {
            "endOffset": 30603,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Compared with baseline levels, hSBA GMTs increased in both groups following each vaccination (Fig. 2D), regardless of age strata (Table S2), with slightly higher values observed in the high-risk group.",
            "startOffset": 30402,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 33202,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The investigators assessed that 2 participants in the high-risk and 1 participant in the control groups had vaccine-related unsolicited AEs.",
            "startOffset": 33062,
            "title": "Safety"
        },
        {
            "endOffset": 25583,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 25582,
                    "startOffset": 25575
                },
                "b0125": {
                    "endOffset": 25582,
                    "startOffset": 25575
                },
                "b0130": {
                    "endOffset": 25582,
                    "startOffset": 25575
                }
            },
            "secId": "s0025",
            "sentence": "We measured serum bactericidal activity by rSBA (Public Health England, United Kingdom) and hSBA (Neomed-Labs inc, Canada) assays [24\u201326].",
            "startOffset": 25445,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 30228,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-dose 1, percentages of children with hSBA titers \u22651:4 were \u226582.9% in the high-risk and \u226575.7% in the control groups.",
            "startOffset": 30107,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 38554,
            "parents": [],
            "secId": "s0070",
            "sentence": "The main strengths of this study included the use of an age-matched group of healthy participants, which allowed a better comparison between groups, and its design as a prospective clinical trial in a vulnerable population.",
            "startOffset": 38331,
            "title": "Discussion"
        },
        {
            "endOffset": 40605,
            "parents": [],
            "secId": "s0080",
            "sentence": "Nimenrix is a trademark of GSK, licensed to Pfizer.",
            "startOffset": 40554,
            "title": "Trademarks"
        },
        {
            "endOffset": 36874,
            "parents": [],
            "secId": "s0070",
            "sentence": "Since meningococcal correlates of protection have been determined based on immune responses in healthy individuals, there has been concern they may not be protective in immunocompromised, high-risk individuals due to impaired splenic activity.",
            "startOffset": 36631,
            "title": "Discussion"
        },
        {
            "endOffset": 38331,
            "parents": [],
            "secId": "s0070",
            "sentence": "Therefore, MenACWY-TT seemed to have an acceptable safety profile in children at increased risk for meningococcal disease.",
            "startOffset": 38209,
            "title": "Discussion"
        },
        {
            "endOffset": 30056,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Compared with baseline levels, overall rSBA GMTs increased post-dose 1 by \u2265152.8- and \u2265354.5-fold and post-dose 2 by \u2265187.1- and \u2265267.3-fold in the high-risk and control groups, respectively (Fig. 2B).",
            "startOffset": 29855,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 28737,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We performed all analyses using the Statistical Analysis System software (SAS SAS Institute Inc., Cary, NC, US).",
            "startOffset": 28625,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33582,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Post-dose 2, there were 3 (7.0%) participants in the high-risk and 8 (18.6%) participants in the control groups who reported unsolicited AEs (not vaccine-related).",
            "startOffset": 33419,
            "title": "Safety"
        },
        {
            "endOffset": 21509,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 21508,
                    "startOffset": 21501
                },
                "b0075": {
                    "endOffset": 21508,
                    "startOffset": 21501
                }
            },
            "secId": "s0005",
            "sentence": "Pneumococcal conjugate vaccines are also effective in children with sickle cell disease [14,15].",
            "startOffset": 21413,
            "title": "Introduction"
        },
        {
            "endOffset": 24430,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We administered the vaccine intramuscularly in the non-dominant deltoid or thigh (dominant deltoid for 1 participant).",
            "startOffset": 24312,
            "title": "Study design and participants"
        },
        {
            "endOffset": 30918,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Post-dose 1, percentages of participants with anti-PS antibody concentrations \u22652.0 \u03bcg/ml ranged from 89.7 to 100% in the high-risk and 94.1\u2013100% in the control groups.",
            "startOffset": 30751,
            "title": "Antibody concentrations"
        },
        {
            "endOffset": 24184,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 24183,
                    "startOffset": 24177
                },
                "b0110": {
                    "endOffset": 24183,
                    "startOffset": 24177
                }
            },
            "secId": "s0015",
            "sentence": "In line with the ACIP recommendations for at-risk individuals, participants from both groups received 2 MenACWY-TT doses administered 2 months apart [8,22].",
            "startOffset": 24028,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32534,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In 6\u201317 year-olds, the most frequently solicited general symptom was fatigue, reported after 39.7% of doses in the high-risk and 24.7% of doses in the control groups (Table 3).",
            "startOffset": 32358,
            "title": "Safety"
        },
        {
            "endOffset": 29336,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Following the first MenACWY-TT dose, rSBA VRRs for each serogroup ranged from 92.5 to 100% in the high-risk and 97.5\u2013100% in the control groups.",
            "startOffset": 29192,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 27269,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0160": {
                    "endOffset": 27268,
                    "startOffset": 27264
                }
            },
            "secId": "s0035",
            "sentence": "To estimate the accuracy which can be expected for this sample size, we calculated exact 95% confidence intervals (CIs) for the percentage of participants anticipated to present a vaccine response (VR), based on results from a previous study in adolescents vaccinated with a single MenACWY-TT dose [32].",
            "startOffset": 26966,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 22031,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 22030,
                    "startOffset": 22024
                },
                "b0085": {
                    "endOffset": 22030,
                    "startOffset": 22024
                }
            },
            "secId": "s0005",
            "sentence": "The United States (US) Food and Drug Administration has approved 2 meningococcal quadrivalent conjugate vaccines against serogroups A, C, W and Y: MenACWY-CRM197 (Menveo, GSK) for individuals aged 2 months\u201355 years and MenACWY-DT (Menactra, Sanofi Pasteur) for individuals aged 9 months\u201355 years [8,17].",
            "startOffset": 21728,
            "title": "Introduction"
        },
        {
            "endOffset": 21245,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 21244,
                    "startOffset": 21238
                },
                "b0050": {
                    "endOffset": 21244,
                    "startOffset": 21238
                }
            },
            "secId": "s0005",
            "sentence": "In the absence of a functional spleen, immune responses to polysaccharide (PS) vaccines are impaired while those to conjugate vaccines are less impacted [9,10].",
            "startOffset": 21085,
            "title": "Introduction"
        },
        {
            "endOffset": 31326,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Compared with baseline levels, anti-PS antibody GMCs increased \u22657.0-fold in the high-risk and \u22656.9-fold in the control groups, post-dose 1, and \u22657.5-fold in the high-risk and \u22655.0-fold in the control groups, post-dose 2 (Fig. 2F).",
            "startOffset": 31096,
            "title": "Antibody concentrations"
        },
        {
            "endOffset": 23197,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We conducted this phase III, open-label, controlled study between September 2012 and March 2015, in 14 centers in the US (12 Kaiser Permanente Vaccine Study Centers and 2 Duke University Hospital centers) and 2 centers in the Czech Republic.",
            "startOffset": 22956,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24734,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 24685,
                    "startOffset": 24681
                }
            },
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki [23] and was approved by Institutional Review Boards.",
            "startOffset": 24583,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39532,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 39484,
                    "startOffset": 39480
                }
            },
            "secId": "s0070",
            "sentence": "The high-risk group also did not include participants with complement deficiency as these cases are usually diagnosed following a meningococcal disease [40] which would have excluded them from enrollment.",
            "startOffset": 39328,
            "title": "Discussion"
        },
        {
            "endOffset": 22678,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 22677,
                    "startOffset": 22670
                },
                "b0095": {
                    "endOffset": 22573,
                    "startOffset": 22566
                },
                "b0100": {
                    "endOffset": 22677,
                    "startOffset": 22670
                }
            },
            "secId": "s0005",
            "sentence": "MenACWY-TT (Nimenrix, Pfizer) uses tetanus toxoid (TT) as a carrier protein [18\u201320] and is approved for use as a single dose in individuals as of 12 months of age in >65 countries [18,20].",
            "startOffset": 22490,
            "title": "Introduction"
        },
        {
            "endOffset": 38852,
            "parents": [],
            "secId": "s0070",
            "sentence": "The study was limited by its small sample size, its open-label design which might have biased the reporting of AEs, and the lack of a control arm receiving another vaccine.",
            "startOffset": 38680,
            "title": "Discussion"
        },
        {
            "endOffset": 23627,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The high-risk group included individuals with anatomic asplenia, some degree of functional asplenia (e.g. sickle-cell anemia, histiocytosis X, celiac disease), complement deficiencies, or if investigators could assess a reduced splenic function by means of an appropriate technique (scintiscan, pitted erythrocyte counting or Howell-Jolly body detection).",
            "startOffset": 23272,
            "title": "Study design and participants"
        },
        {
            "endOffset": 27823,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We defined rSBA VRs as post-vaccination rSBA titers \u22651:32 for initially seronegative participants (i.e. baseline rSBA titer <1:8) and as 4-fold increases in rSBA titers compared with baseline titers for initially seropositive participants.",
            "startOffset": 27584,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 28990,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The high-risk group included 33 splenectomized and 10 hyposplenic patients.",
            "startOffset": 28915,
            "title": "Demographics"
        },
        {
            "endOffset": 40153,
            "parents": [],
            "secId": "s0075",
            "sentence": "Our study demonstrated for the first time that 1 or 2 MenACWY-TT doses induced functional (rSBA and hSBA) and anti-PS antibodies to the 4 serogroups in children and adolescents at high-risk for meningococcal disease.",
            "startOffset": 39937,
            "title": "Conclusion"
        },
        {
            "endOffset": 29679,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Post dose-2, hSBA VRRs increased to 73.0\u2013100% in the high-risk and 73.0\u201385.3% in the control groups (Table 2, Table S1).",
            "startOffset": 29559,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 30750,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "In both groups, \u226460% of participants had pre-vaccination anti-PS antibody concentrations \u22652.0 \u03bcg/ml for each serogroup.",
            "startOffset": 30631,
            "title": "Antibody concentrations"
        },
        {
            "endOffset": 34282,
            "parents": [],
            "secId": "s0070",
            "sentence": "This study showed that functional antibodies elicited by 1 or 2 MenACWY-TT doses, as measured by hSBA and rSBA assays, were not impaired in children and adolescents at increased risk for meningococcal disease compared with healthy controls.",
            "startOffset": 34042,
            "title": "Discussion"
        },
        {
            "endOffset": 28082,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We defined hSBA VRs as post-vaccination hSBA titers \u22651:8 for initially seronegative participants (i.e. baseline hSBA titer <1:4), and as a 4-fold increases in post-vaccination hSBA titers compared with baseline titers for initially seropositive participants.",
            "startOffset": 27824,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38208,
            "parents": [],
            "secId": "s0070",
            "sentence": "In our study, more SAEs were observed in high-risk participants than in controls, but they were due to infections and complications consistent with their underlying conditions.",
            "startOffset": 38032,
            "title": "Discussion"
        },
        {
            "endOffset": 35359,
            "parents": [],
            "secId": "s0070",
            "sentence": "Overall, our study found that immune responses to 2 doses of MenACWY-TT were comparable in the high-risk and control groups.",
            "startOffset": 35235,
            "title": "Discussion"
        },
        {
            "endOffset": 40941,
            "parents": [],
            "secId": "s0085",
            "sentence": "GlaxoSmithKline Biologicals SA also took in charge all costs associated to the development and publishing of the present manuscript.",
            "startOffset": 40809,
            "title": "Funding"
        },
        {
            "endOffset": 30107,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "rSBA GMTs by age strata are presented in Table S2.",
            "startOffset": 30057,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 36144,
            "parents": [],
            "secId": "s0070",
            "sentence": "In the current study, when we used hSBA assays, VRRs were lower but comparable between groups (\u226555.6% post-dose 1 and \u226573.0% post-dose 2), and similar or even higher compared with reports from previous studies in healthy 10\u201325-year-olds and toddlers.",
            "startOffset": 35894,
            "title": "Discussion"
        },
        {
            "endOffset": 31096,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Post-dose 2, percentages of participants with anti-PS antibody concentrations \u22652.0 \u03bcg/ml ranged from 90.9 to 100% in the high-risk and 84.4\u2013100% in the control groups (Fig. 2E).",
            "startOffset": 30919,
            "title": "Antibody concentrations"
        },
        {
            "endOffset": 40510,
            "parents": [],
            "secId": "s0080",
            "sentence": "MenHibrix and Menveo are trademarks of GSK.",
            "startOffset": 40467,
            "title": "Trademarks"
        },
        {
            "endOffset": 26594,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "We collected serious AEs (SAEs) and new onset chronic illnesses (NOCIs) during a 6-month follow-up post-dose 2.",
            "startOffset": 26483,
            "title": "Safety"
        },
        {
            "endOffset": 28624,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We calculated the incidence of solicited and unsolicited AEs, grade 3 AEs, and vaccine-related AEs with 95% CIs for each group, as the percentage of total administered doses that were followed by at least one AE.",
            "startOffset": 28412,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 30401,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-dose 2, all participants achieved hSBA titers \u22651:4, except for MenA (94.6% of participants in the high-risk and 80.6% of participants in the control groups) (Fig. 2C).",
            "startOffset": 30229,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 32704,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "There was no fever reported in 1\u20135 year-olds, while among 6\u201317 year-olds, we recorded fever after 5.1% of doses in the high-risk and 2.6% of doses in the control groups.",
            "startOffset": 32535,
            "title": "Safety"
        },
        {
            "endOffset": 23883,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Children aged <2 years with functional or anatomic asplenia were not enrolled.",
            "startOffset": 23805,
            "title": "Study design and participants"
        },
        {
            "endOffset": 33970,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "All SAEs resolved without sequelae.",
            "startOffset": 33935,
            "title": "Safety"
        },
        {
            "endOffset": 40553,
            "parents": [],
            "secId": "s0080",
            "sentence": "Menactra is a trademark of Sanofi Pasteur.",
            "startOffset": 40511,
            "title": "Trademarks"
        },
        {
            "endOffset": 26719,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "A non-exhaustive list of illnesses recorded as NOCIs includes auto-immune disorders, allergies, type 1 diabetes, and asthma.",
            "startOffset": 26595,
            "title": "Safety"
        },
        {
            "endOffset": 41884,
            "parents": [],
            "secId": "s0095",
            "sentence": "PK received an institutional grant from Pfizer.",
            "startOffset": 41837,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 21085,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 21084,
                    "startOffset": 21079
                },
                "b0040": {
                    "endOffset": 21084,
                    "startOffset": 21079
                }
            },
            "secId": "s0005",
            "sentence": "Many countries recommend vaccination against meningococcal disease in individuals with specific risk factors, including complement deficiencies, functional or anatomic asplenia, human immunodeficiency virus (HIV), community outbreak of meningococcal disease, travelling to high-risk countries, students living in residential housing, or microbiologists exposed to N. meningitidis [1,8].",
            "startOffset": 20699,
            "title": "Introduction"
        },
        {
            "endOffset": 36980,
            "parents": [],
            "secId": "s0070",
            "sentence": "Therefore, we also quantified immune responses to MenACWY-TT in terms of anti-PS antibody concentrations.",
            "startOffset": 36875,
            "title": "Discussion"
        },
        {
            "endOffset": 40253,
            "parents": [],
            "secId": "s0075",
            "sentence": "MenACWY-TT had a clinically acceptable safety profile in both high-risk and background-risk groups.",
            "startOffset": 40154,
            "title": "Conclusion"
        },
        {
            "endOffset": 41400,
            "parents": [],
            "secId": "s0090",
            "sentence": "NK, TH, and NS were involved in subject recruitment and sample processing.",
            "startOffset": 41326,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 34660,
            "parents": [],
            "secId": "s0070",
            "sentence": "Prior studies have assessed immune responses to MenC in high-risk individuals by rSBA, but no data on protection against the other meningococcal serogroups in this special population exists.",
            "startOffset": 34470,
            "title": "Discussion"
        },
        {
            "endOffset": 24028,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The control group included healthy individuals who were age-matched to high-risk participants according to 1\u20135, 6\u201310 and 11\u201317 years age strata.",
            "startOffset": 23884,
            "title": "Study design and participants"
        },
        {
            "endOffset": 19868,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 19867,
                    "startOffset": 19862
                },
                "b0010": {
                    "endOffset": 19867,
                    "startOffset": 19862
                }
            },
            "secId": "s0005",
            "sentence": "The most common clinical presentations of Neisseria meningitidis infection are meningitis and septicemia [1,2].",
            "startOffset": 19757,
            "title": "Introduction"
        },
        {
            "endOffset": 31398,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Anti-TT antibody concentrations are presented in Supplementary Table S3.",
            "startOffset": 31326,
            "title": "Antibody concentrations"
        },
        {
            "endOffset": 39138,
            "parents": [],
            "secId": "s0070",
            "sentence": "Also, the results of analyses of immunogenicity performed by pre-vaccination status and age strata should be interpreted cautiously due to the limited number of participants in each category.",
            "startOffset": 38947,
            "title": "Discussion"
        },
        {
            "endOffset": 37350,
            "parents": [],
            "secId": "s0070",
            "sentence": "Although limited by the small sample size, our data suggest that the ability to produce antibodies against the 4 serogroups was not impacted by the condition of the participants.",
            "startOffset": 37172,
            "title": "Discussion"
        },
        {
            "endOffset": 20331,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 20330,
                    "startOffset": 20323
                },
                "b0020": {
                    "endOffset": 20330,
                    "startOffset": 20323
                },
                "b0025": {
                    "endOffset": 20330,
                    "startOffset": 20323
                },
                "b0030": {
                    "endOffset": 20330,
                    "startOffset": 20323
                }
            },
            "secId": "s0005",
            "sentence": "Individuals with medical conditions such as complement deficiencies and splenic dysfunction/asplenia have impaired immune function and lack protective bactericidal activity, and are therefore more vulnerable to infections with encapsulated bacteria [1,4\u20136].",
            "startOffset": 20074,
            "title": "Introduction"
        },
        {
            "endOffset": 32967,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Among 6\u201317 year-olds, grade 3 symptoms were reported after \u22641.3% of doses in the high-risk and \u22642.6% of doses in the control groups (Table 3).",
            "startOffset": 32825,
            "title": "Safety"
        },
        {
            "endOffset": 32357,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The most frequently reported solicited general symptoms in 1\u20135 year-olds were drowsiness in the high-risk group (after 50.0% [3/6] of doses), and drowsiness and irritability in the control group (after 40.0% [2/5] of doses).",
            "startOffset": 32133,
            "title": "Safety"
        },
        {
            "endOffset": 21412,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 21339,
                    "startOffset": 21336
                },
                "b0055": {
                    "endOffset": 21321,
                    "startOffset": 21314
                },
                "b0060": {
                    "endOffset": 21321,
                    "startOffset": 21314
                },
                "b0065": {
                    "endOffset": 21352,
                    "startOffset": 21348
                }
            },
            "secId": "s0005",
            "sentence": "Studies have shown that monovalent meningococcal serogroup C (MenC) [11,12], pneumococcal [9] and Hib [13] conjugate vaccines are immunogenic in asplenic individuals.",
            "startOffset": 21246,
            "title": "Introduction"
        },
        {
            "endOffset": 26213,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0155": {
                    "endOffset": 26197,
                    "startOffset": 26193
                }
            },
            "secId": "s0025",
            "sentence": "We measured anti-TT antibody concentrations by an in-house enzyme-linked immunosorbent assay with cut-offs of 0.1 International Units (IU)/ml (considered as protective [31]) and 1.0 IU/ml.",
            "startOffset": 26025,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35734,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 35733,
                    "startOffset": 35729
                }
            },
            "secId": "s0070",
            "sentence": "In a previous study, \u226587.5% of healthy 1\u201310-year-olds had rSBA titers \u22651:8 after 1 dose of MenACWY-TT [33].",
            "startOffset": 35627,
            "title": "Discussion"
        },
        {
            "endOffset": 33418,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Two participants in the high-risk group had unsolicited grade 3 AEs (conjunctivitis and pain in the extremities), while in the control group, 3 participants reported grade 3 otitis externa, scarlet fever and asthma.",
            "startOffset": 33203,
            "title": "Safety"
        },
        {
            "endOffset": 42121,
            "parents": [],
            "secId": "s0095",
            "sentence": "JMM and MVDW own shares/restricted shares in GSK.",
            "startOffset": 42072,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 27584,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We performed safety analyses on the total vaccinated cohort, including all participants who received \u22651 vaccine dose, and immunogenicity analyses on the according-to-protocol (ATP) immunogenicity cohort, including all evaluable participants who received both vaccine doses and with available immunogenicity results.",
            "startOffset": 27269,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 35626,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 35625,
                    "startOffset": 35621
                }
            },
            "secId": "s0070",
            "sentence": "In our study, rSBA VRRs following MenACWY-TT vaccination were \u226592.5% post-dose 1 and 100% post-dose 2 in both groups, which is in line with previous trials which used rSBA to assess the immunogenicity of MenACWY-TT in healthy toddlers, children, and adolescents [18].",
            "startOffset": 35359,
            "title": "Discussion"
        },
        {
            "endOffset": 40808,
            "parents": [],
            "secId": "s0085",
            "sentence": "GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis as well as the development of the manuscript and its approval for submission.",
            "startOffset": 40612,
            "title": "Funding"
        },
        {
            "endOffset": 42071,
            "parents": [],
            "secId": "s0095",
            "sentence": "MH was consultant of Chiltern International for GSK at the time the study was conducted.",
            "startOffset": 41983,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 33880,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "There were 5 SAEs recorded, 4 in the high-risk group (cystitis due to Escherichia coli, pneumococcal bacteremia, salmonellosis and sickle-cell anemia with crisis), and 1 in the control group (joint injury).",
            "startOffset": 33674,
            "title": "Safety"
        },
        {
            "endOffset": 40364,
            "parents": [],
            "secId": "s0075",
            "sentence": "These results support the use of MenACWY-TT in high-risk groups, especially asplenic children and adolescents.",
            "startOffset": 40254,
            "title": "Conclusion"
        },
        {
            "endOffset": 32824,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Among 1\u20135 year-olds, we recorded grade 3 drowsiness and irritability after 16.7% (1/5) of doses in the high-risk group.",
            "startOffset": 32705,
            "title": "Safety"
        },
        {
            "endOffset": 22916,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we evaluated the immunogenicity, safety and reactogenicity of 1 or 2 MenACWY-TT doses administered to 1\u201317-year-old children and adolescents at increased risk for meningococcal disease compared with age-matched healthy individuals.",
            "startOffset": 22679,
            "title": "Introduction"
        },
        {
            "endOffset": 31727,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In 6\u201317 year-olds, pain was reported after 73.1% of doses in the high-risk and 61.0% of doses in the control groups.",
            "startOffset": 31611,
            "title": "Safety"
        },
        {
            "endOffset": 28412,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We assessed the percentages of participants with rSBA/hSBA VRs (VRRs), rSBA titers \u22651:8, hSBA titers \u22651:4, anti-PS antibody concentrations \u22652.0 \u03bcg/ml and anti-TT concentrations \u22650.1 IU/ml and \u22651.0 IU/ml, and antibody geometric mean titers/concentrations (GMTs/GMCs) against each vaccine antigen with exact 95% CIs in both groups.",
            "startOffset": 28083,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 28914,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Of 86 participants enrolled, 83 completed the vaccination phase of the study; we maintained contact with all 83 throughout the 6-month follow-up (Fig. 1).",
            "startOffset": 28760,
            "title": "Demographics"
        },
        {
            "endOffset": 23804,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 23803,
                    "startOffset": 23799
                }
            },
            "secId": "s0015",
            "sentence": "Individuals with sickle-cell disease were enrolled without assessing splenic function because sickle-cell disease is invariably associated with severe splenic dysfunction [21].",
            "startOffset": 23628,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31610,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In 1\u20135 year-olds, pain was reported after 50.0% (3/6) of doses in the high-risk and 20.0% (1/5) of doses in the control groups.",
            "startOffset": 31483,
            "title": "Safety"
        },
        {
            "endOffset": 31836,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In 1\u20135 year-olds, redness and swelling were only reported in the high-risk group (following 33.3% of doses).",
            "startOffset": 31728,
            "title": "Safety"
        },
        {
            "endOffset": 25240,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary objective was to assess the immunogenicity of MenACWY-TT administered to high-risk participants as a 2-dose schedule compared with age-matched control participants, in terms of serum bactericidal activity vaccine response rates (VRRs) for MenA, MenC, MenW and MenY, using rabbit (rSBA) or human (hSBA) complement assays.",
            "startOffset": 24908,
            "title": "Study objectives"
        },
        {
            "endOffset": 29066,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Groups were balanced in terms of age, gender, and race/ethnicity (Table 1).",
            "startOffset": 28991,
            "title": "Demographics"
        },
        {
            "endOffset": 41325,
            "parents": [],
            "secId": "s0090",
            "sentence": "NK, JMM, MVDW, and DK conceived and designed the experiments.",
            "startOffset": 41264,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 41514,
            "parents": [],
            "secId": "s0090",
            "sentence": "NK, MH, and TH performed the study and NK, DK, and MH were involved in data analysis, interpretation and writing.",
            "startOffset": 41401,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 23271,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We enrolled 1\u201317-year-old participants in a high-risk and a control group.",
            "startOffset": 23197,
            "title": "Study design and participants"
        },
        {
            "endOffset": 25350,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The secondary objectives compared the immunogenicity, safety and reactogenicity of MenACWY-TT in both groups.",
            "startOffset": 25241,
            "title": "Study objectives"
        },
        {
            "endOffset": 31935,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In 6\u201317 year-olds, redness and swelling were reported in both groups (range: 24.4\u201330.8% of doses).",
            "startOffset": 31837,
            "title": "Safety"
        },
        {
            "endOffset": 36362,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 36314,
                    "startOffset": 36310
                },
                "b0185": {
                    "endOffset": 36256,
                    "startOffset": 36252
                }
            },
            "secId": "s0070",
            "sentence": "Our results were consistent with those from 2 studies in 10\u201325-year-olds reporting hSBA VRRs of 51.0\u201382.5% [37] and hSBA titers \u22651:4 achieved by \u226583.0% of vaccinees [32] across all serogroups, after 1 MenACWY-TT dose.",
            "startOffset": 36145,
            "title": "Discussion"
        },
        {
            "endOffset": 35012,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 35011,
                    "startOffset": 35007
                }
            },
            "secId": "s0070",
            "sentence": "In a previous study, rSBA titers against MenC did not differ between asplenic adolescents and adults with \u03b2-thalassemia and age-matched healthy controls at 1 month post-immunization with a monovalent MenC conjugate vaccine [12].",
            "startOffset": 34784,
            "title": "Discussion"
        },
        {
            "endOffset": 26482,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "We recorded solicited local and general AEs for 4 days and unsolicited AEs for 31 days post-immunization and evaluated the intensity of each symptom on a 3-grade scale.",
            "startOffset": 26314,
            "title": "Safety"
        },
        {
            "endOffset": 34783,
            "parents": [],
            "secId": "s0070",
            "sentence": "Our study provides valuable information on the protection against other meningococcal serogroups in high-risk individuals.",
            "startOffset": 34661,
            "title": "Discussion"
        },
        {
            "endOffset": 37171,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 37170,
                    "startOffset": 37166
                }
            },
            "secId": "s0070",
            "sentence": "Anti-PS antibody levels were similar in both groups, which is in line with a previous study evaluating the immunogenicity of a monovalent MenC conjugate vaccine in asplenic individuals [11].",
            "startOffset": 36981,
            "title": "Discussion"
        },
        {
            "endOffset": 25869,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 25868,
                    "startOffset": 25864
                }
            },
            "secId": "s0025",
            "sentence": "We also measured anti-PS immunoglobulin G concentrations using an enzyme-linked immunosorbent assay [29].",
            "startOffset": 25764,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 29558,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-dose 1, hSBA VRRs ranged from 55.6 to 77.1% in the high-risk and 60.6\u201376.3% in the control groups.",
            "startOffset": 29455,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 33674,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "One participant from the control group reported a grade 3 unsolicited AE (radius fracture).",
            "startOffset": 33583,
            "title": "Safety"
        },
        {
            "endOffset": 26314,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Parents/legally acceptable representatives reported all adverse events (AEs) on diary cards.",
            "startOffset": 26222,
            "title": "Safety"
        },
        {
            "endOffset": 39327,
            "parents": [],
            "secId": "s0070",
            "sentence": "Another limitation was the small number of 1\u20135 year-olds, which could be explained by the strong recommendations to vaccinate young infants at increased risk against meningococcal disease.",
            "startOffset": 39139,
            "title": "Discussion"
        },
        {
            "endOffset": 41836,
            "parents": [],
            "secId": "s0095",
            "sentence": "TH and PK received an institutional grant from GSK to conduct this study.",
            "startOffset": 41763,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 26965,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Assuming a 10% dropout rate, we calculated a sample size of 50 participants per group to allow for 45 evaluable participants in each group.",
            "startOffset": 26826,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 35234,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 35233,
                    "startOffset": 35229
                }
            },
            "secId": "s0070",
            "sentence": "In another study, 2 doses of monovalent MenC conjugate vaccines elicited significantly lower rSBA titers in asplenic individuals than in healthy controls, but up to 93% of asplenic patients achieved rSBA titers \u22651:8 [11].",
            "startOffset": 35013,
            "title": "Discussion"
        },
        {
            "endOffset": 38680,
            "parents": [],
            "secId": "s0070",
            "sentence": "The study used a strict definition for asplenia and assessed a vaccination schedule recommended by ACIP for high-risk groups.",
            "startOffset": 38555,
            "title": "Discussion"
        },
        {
            "endOffset": 20698,
            "parents": [],
            "secId": "s0005",
            "sentence": "Immunizing these vulnerable patients against N. meningitidis, Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) is an important strategy to prevent encapsulated bacterial infections.",
            "startOffset": 20501,
            "title": "Introduction"
        },
        {
            "endOffset": 25444,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "We collected blood samples at pre-vaccination and at 1 month after each dose.",
            "startOffset": 25367,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 42161,
            "parents": [],
            "secId": "s0095",
            "sentence": "MH, NS declare no conflict of interest.",
            "startOffset": 42122,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 41107,
            "parents": [],
            "secId": "s0090",
            "sentence": "All authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.",
            "startOffset": 40962,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 29854,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-dose 1 and 2, percentages of children with rSBA titers \u22651:8 were \u226592.5% and 100% in the high-risk group, and \u226597.5% and 100% in the control group, respectively (Fig. 2A).",
            "startOffset": 29679,
            "title": "Bactericidal activity"
        },
        {
            "endOffset": 32133,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "We recorded no grade 3 local symptoms in 1\u20135 year-old children, while in 6\u201317 year-olds, they were reported after \u22646.4% of doses in the high-risk and \u22645.2% of doses in the control groups (Table 3).",
            "startOffset": 31936,
            "title": "Safety"
        },
        {
            "endOffset": 21728,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 21727,
                    "startOffset": 21718
                },
                "b0055": {
                    "endOffset": 21727,
                    "startOffset": 21718
                },
                "b0080": {
                    "endOffset": 21727,
                    "startOffset": 21718
                }
            },
            "secId": "s0005",
            "sentence": "A possible explanation is that coupling of PSs to carrier proteins induces T-cell dependent antibody responses, which may allow secondary lymphoid tissues to compensate for the absence of a functional spleen [9,11,16].",
            "startOffset": 21510,
            "title": "Introduction"
        },
        {
            "endOffset": 37541,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 37540,
                    "startOffset": 37536
                }
            },
            "secId": "s0070",
            "sentence": "However, other studies reported significantly lower anti-PS antibody concentrations in asplenic patients compared with healthy individuals following a monovalent MenC conjugate vaccine [12].",
            "startOffset": 37351,
            "title": "Discussion"
        },
        {
            "endOffset": 37786,
            "parents": [],
            "secId": "s0070",
            "sentence": "Although the limited number of 1\u20135 year-old children (3 in each study group) did not allow us to draw any conclusion, solicited local symptoms in this age category seemed to occur more frequently in the high-risk compared with the control group.",
            "startOffset": 37541,
            "title": "Discussion"
        },
        {
            "endOffset": 41762,
            "parents": [],
            "secId": "s0095",
            "sentence": "NK reports grants from GSK, during the conduct of the study; grants from Sanofi Pasteur, Novartis, Merck & Co, Pfizer, Protein Science, MedImmune, Centers for Disease Control and Prevention, and GSK, outside the submitted work.",
            "startOffset": 41535,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 25764,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 25718,
                    "startOffset": 25711
                },
                "b0135": {
                    "endOffset": 25763,
                    "startOffset": 25756
                },
                "b0140": {
                    "endOffset": 25763,
                    "startOffset": 25756
                }
            },
            "secId": "s0025",
            "sentence": "We used an rSBA titer of 1:8 and an hSBA titer of 1:4 as serological correlates of protection, which were established for MenC [24,27] and extended to the other serogroups [27,28].",
            "startOffset": 25584,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31482,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Pain at injection site was the most frequently reported solicited local AE.",
            "startOffset": 31407,
            "title": "Safety"
        },
        {
            "endOffset": 29149,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The ATP cohort for immunogenicity included 40 participants in each group (Fig. 1).",
            "startOffset": 29067,
            "title": "Demographics"
        },
        {
            "endOffset": 36631,
            "parents": [],
            "refoffsets": {
                "b0190": {
                    "endOffset": 36426,
                    "startOffset": 36422
                }
            },
            "secId": "s0070",
            "sentence": "Compared with data in toddlers receiving 1 MenACWY-TT dose [38], the percentage of participants with hSBA titers \u22651:4 post-dose 1 in our study appeared similar for MenA and MenC (75.7\u201394.7% versus 70.3\u201394.6%) and higher for MenW and MenY (91.9\u2013100% versus 20.5\u201359.8%).",
            "startOffset": 36363,
            "title": "Discussion"
        },
        {
            "endOffset": 38946,
            "parents": [],
            "secId": "s0070",
            "sentence": "Moreover, comparisons between groups were descriptive and should be interpreted with caution.",
            "startOffset": 38853,
            "title": "Discussion"
        },
        {
            "endOffset": 34031,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "There were no NOCIs and no deaths reported during the study.",
            "startOffset": 33971,
            "title": "Safety"
        },
        {
            "endOffset": 41919,
            "parents": [],
            "secId": "s0095",
            "sentence": "JMM and MVDW are employees of GSK.",
            "startOffset": 41885,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 33061,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Post-dose 1, there were 7 (16.3%) participants from each group who reported \u22651 unsolicited AE.",
            "startOffset": 32967,
            "title": "Safety"
        },
        {
            "endOffset": 20073,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 20072,
                    "startOffset": 20067
                },
                "b0015": {
                    "endOffset": 20072,
                    "startOffset": 20067
                }
            },
            "secId": "s0005",
            "sentence": "Symptoms of invasive meningococcal disease, including fever, loss of appetite, irritability, lethargy, nausea, vomiting, diarrhea, photophobia and convulsions, usually occur 1\u20134 days post-infection [2,3].",
            "startOffset": 19869,
            "title": "Introduction"
        },
        {
            "endOffset": 33934,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "None were considered causally related to vaccination.",
            "startOffset": 33881,
            "title": "Safety"
        },
        {
            "endOffset": 22490,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 22489,
                    "startOffset": 22481
                },
                "b0040": {
                    "endOffset": 22489,
                    "startOffset": 22481
                },
                "b0085": {
                    "endOffset": 22489,
                    "startOffset": 22481
                }
            },
            "secId": "s0005",
            "sentence": "In addition to routine vaccination of adolescents, the US Advisory Committee on Immunization Practices (ACIP) recommends immunization of infants and toddlers at increased risk for meningococcal disease with either MenACWY-CRM197 or Hib-MenCY-TT (MenHibrix, GSK) at 2, 4, 6, and 12 months of age or with MenACWY-DT at 9 and 12 months of age, while individuals aged 2\u201355 years should receive 2 doses (8\u201312 weeks apart) of MenACWY-CRM197 or MenACWY-DT [2,8,17].",
            "startOffset": 22032,
            "title": "Introduction"
        },
        {
            "endOffset": 24889,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A protocol summary is available at http://www.gsk-clinicalstudyregister.com (ID: 115524).",
            "startOffset": 24800,
            "title": "Study design and participants"
        },
        {
            "endOffset": 26803,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The investigators assessed the possible relationships between AEs and immunization.",
            "startOffset": 26720,
            "title": "Safety"
        },
        {
            "endOffset": 41982,
            "parents": [],
            "secId": "s0095",
            "sentence": "DK was an employee of GSK at the time the study was conducted.",
            "startOffset": 41920,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 24799,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This study is registered at www.clinicaltrials.gov (NCT01641042).",
            "startOffset": 24734,
            "title": "Study design and participants"
        },
        {
            "endOffset": 26025,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0150": {
                    "endOffset": 26024,
                    "startOffset": 26020
                }
            },
            "secId": "s0025",
            "sentence": "We considered antibody concentrations \u22652.0 \u03bcg/ml as protective since this threshold has been correlated with protection for MenA and MenC PS vaccines [30].",
            "startOffset": 25870,
            "title": "Immunogenicity"
        }
    ],
    "docId": "S0264410X18302846",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Nicola.Klein@kp.org",
                "first": "Nicola P.",
                "initial": "N.P.",
                "last": "Klein"
            },
            {
                "email": "habanec.tomas@fnbrno.cz",
                "first": "Tomas",
                "initial": "T.",
                "last": "Habanec"
            },
            {
                "email": "Kosinpav@seznam.cz",
                "first": "Pavel",
                "initial": "P.",
                "last": "Kosina"
            },
            {
                "email": "nirmish.shah@duke.edu",
                "first": "Nirmish R.",
                "initial": "N.R.",
                "last": "Shah"
            },
            {
                "email": "devayani2000in@yahoo.co.in",
                "first": "Devayani",
                "initial": "D.",
                "last": "Kolhe"
            },
            {
                "email": "jacqueline.m.miller@gsk.com",
                "first": "Jacqueline M.",
                "initial": "J.M.",
                "last": "Miller"
            },
            {
                "email": "mhezareh@yahoo.com",
                "first": "Marjan",
                "initial": "M.",
                "last": "Hezareh"
            },
            {
                "email": "marie.x.van-der-wielen@gsk.com",
                "first": "Marie",
                "initial": "M.",
                "last": "Van der Wielen"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.02.085",
        "firstpage": "2356",
        "issn": "0264410X",
        "keywords": [
            "Asplenia",
            "Immunogenicity",
            "Meningococcal disease",
            "Meningococcal vaccine",
            "Neisseria meningitidis",
            "Safety"
        ],
        "lastpage": "2363",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study"
    }
}